China
Africa
Explore chapters and articles related to this topic
Bimatoprost
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Bimatoprost is a synthetic prostamide and structural prostaglandin analog with ocular hypotensive activity. It mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensiti- ve outflow pathway (the uveoscleral routes). Bimatoprost ophthalmic solution is used as an antihypertensive agent for controlling the progression of open-angle glaucoma or ocular hypertension (1).
Pattern hair loss: Pathogenesis, clinical features, diagnosis, and management
Published in Jerry Shapiro, Nina Otberg, Hair Loss and Restoration, 2015
The prostaglandin F2α analogs latanoprost and bimatoprost are used in treating ocular hypertension and glaucoma. A noted side effect is increased eyelash hair growth, a feature that has been investigated in several studies. Bimatoprost is now available as a treatment for eyelash growth [137]. More recently, latanoprost has been investigated for its potential to promote scalp hair growth. Latanoprost significantly increased hair density compared with baseline and placebo and may also encourage pigmentation [138]. Another recent study showed that topical bimatoprost 0.3% applied once daily significantly increased scalp hair growth compared to vehicle in subjects with mild to moderate AGA. However, the same study showed that topical minoxidil 5% applied twice daily in an open-label manner showed higher efficacy than any of the bimatoprost doses tested [139].
Medical Therapy for Glaucoma
Published in Neil T. Choplin, Carlo E. Traverso, Atlas of Glaucoma, 2014
Jennifer E. Williamson, Janet B. Serle
The degree of conjunctival hyperemia associated with these agents is generally mild and rarely a cause for discontinuation of therapy. Bimatoprost has been reported to cause the greatest degree of conjunctival hyperemia and latanoprost the least degree of hyperemia. Recently, bimatoprost was approved in a 0.01% concentration (versus 0.03%) and reportedly has less hyperemia while maintaining efficacy. The 0.03% formulation has been withdrawn from the U.S. market. Individual patients may have enhanced responses or improved tolerability to one of these compounds. Thus, in individual patients experiencing side effects or in patients having less than expected IOP reductions, substitution of a different prostaglandin may occasionally lead to enhanced IOP control and/or to a reduction in side effects, such as hyperemia and foreign-body sensation.
Sustained release ocular drug delivery systems for glaucoma therapy
Published in Expert Opinion on Drug Delivery, 2023
Zinah K. Al-Qaysi, Ian G. Beadham, Sianne L. Schwikkard, Joseph C. Bear, Ali A. Al-Kinani, Raid G. Alany
In 2019, a phase Ib study assessing the safety and efficacy of an ocular insert containing a combination of bimatoprost and timolol for more significant IOP reduction was completed. The purpose of this study was to determine if a combination of these two drugs delivered to the surface of the eye over 10 weeks is superior at lowering (IOP) than either of the drugs delivered alone [91]. The combination eye drop Ganfort® (bimatoprost 0.03% and timolol 0.5%), caused a superior reduction in IOP with a more rapid onset of action due to the complementary mechanisms of action of each drug [11,92]. However, systemic adverse effects from the β-blocker, including hypotension, bradycardia, irregular pulse, and bronchospasm, resulted in decreased patient compliance. Less serious local adverse reactions related to bimatoprost, including eyelash lengthening, hyperemia, eyelid, and iris pigmentation may also decrease patient compliance.
Long-acting ocular drug delivery technologies with clinical precedent
Published in Expert Opinion on Drug Delivery, 2022
Matthew N. O’Brien Laramy, Karthik Nagapudi
Bimatoprost is a prostaglandin agonist approved as a topical ophthalmic solution to treat high pressure in the eye resulting from OAG or OH. However, the elimination half-life of bimatoprost is less than one hour, and thus frequent topical administration is required. Durysta® was developed as a long-acting intracameral implant of bimatoprost to reduce dose frequency and intraocular pressure. Durysta® is supplied as a rod-shaped implant pre-loaded in a sterile single-use 28-gauge injector to allow for an in-office injection procedure. Durysta® contains 10 mg of bimatoprost in a poly (D,L-lactide) (PLA), PLGA, and poly(ethylene glycol) (PEG) 3350 matrix. Interestingly, when compared to Ozurdex®, Durysta® contains PLA and PEG3350 as additional components. PLA has likely been added to the implant to extend the duration of action of Durysta® [83].
Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis
Published in Current Medical Research and Opinion, 2019
George Rennie, Angus Wilkinson, Andrew White, Marinella Ruospo, Armando Teixeira-Pinto, Giovanni Strippoli
Among the included trials, Oddone et al. provided the only significant difference between intervention types, where bimatoprost resulted in a higher post-intervention mean ocular perfusion pressure than timolol30 (Figure 3). This study included POAG and OHT subjects. This may be due to the superior ocular hypotensive effect of bimatoprost relative to timolol or its favourable systemic haemodynamic effects, i.e. no change or an increase in systemic haemodynamics. There is some evidence of the superior ocular hypotensive effect of prostaglandins as a class when compared to beta-blockers and evidence suggesting the ocular hypotensive superiority of bimatoprost within its class17,34–39. In the Oddone et al. study, bimatoprost significantly decreased IOP relative to timolol30. A meta-analysis showed that bimatoprost resulted in the greatest reduction in IOP fluctuations which may suggest that consistency in an ocular hypotensive effect may be necessary in improving ocular perfusion pressure40. A retrospective case series of prostaglandin non-responders in a normal tension glaucoma population showed significantly lower non-response rates in bimatoprost compared to latanoprost, travaprost and tafluprost41. This suggests that there may be unique effects of bimatoprost on aqueous flow which increase efficacy, decrease IOP fluctuations and decrease the rate of non-responders.